MICHAEL M WICK, M.D.
Osteopathic Medicine at Woodside Rd, Redwood City, CA

License number
California 37261
Category
Osteopathic Medicine
Type
Procedural Dermatology
Address
Address
2995 Woodside Rd STE 400, Redwood City, CA 94062
Phone
(650) 845-7711

Professional information

Michael M Wick Photo 1

Dr. Michael M Wick, Woodside CA - MD (Doctor of Medicine)

Address:
2995 Woodside Rd STE 400, Woodside 94062
(650) 845-7711 (Phone)
Education:
Medical Schools
Harvard Medical School
Graduated: 1973


Michael Wick Photo 2

Sensitization To Another Anticancer Therapy And/Or Amelioration Of A Side Effect Of Another Anticancer Therapy By Treatment With A Gst-Activated Anticancer Compound

US Patent:
8207121, Jun 26, 2012
Filed:
Oct 15, 2007
Appl. No.:
11/872662
Inventors:
Gail L. Brown - Woodside CA, US
James G. Keck - Redwood City CA, US
Michael M. Wick - Woodside CA, US
Assignee:
Telik, Inc. - Palo Alto CA
International Classification:
A61P 35/00, G01N 33/574, C12N 5/09
US Classification:
514 193, 435 723, 435344, 436 64
Abstract:
A method of sensitizing a mammal, especially a human, to another anticancer therapy by administering a sensitizing effective amount of a GST-activated anticancer compound. A method of ameliorating a side effect of another anticancer therapy in a mammal, especially a human, by administering an ameliorating effective amount of a GST-activated anticancer compound. Pharmaceutical compositions for the methods. The GST-activated anticancer compound is preferably a compound of U. S. Pat. No. 5,556,942, and more preferably canfosfamide, especially as the hydrochloride salt.


Michael Wick Photo 3

Sensitization To Another Anticancer Therapy And/Or Amelioration Of A Side Effect Of Another Anitcancer Therapy By Treatment With A Gst-Activated Anticancer Compound

US Patent:
2005026, Nov 24, 2005
Filed:
May 19, 2005
Appl. No.:
11/133833
Inventors:
Gail Brown - Woodside CA, US
James Keck - Redwood City CA, US
Michael Wick - Woodside CA, US
International Classification:
A61K038/05
US Classification:
514018000
Abstract:
A method of sensitizing a mammal, especially a human, to another anticancer therapy by administering a sensitizing effective amount of a GST-activated anticancer compound. A method of ameliorating a side effect of another anticancer therapy in a mammal, especially a human, by administering an ameliorating effective amount of a GST-activated anticancer compound. Pharmaceutical compositions for the methods. The GST-activated anticancer compound is preferably a compound of U.S. Pat. No. 5,556,942, and more preferably canfosfamide, especially as the hydrochloride salt.


Michael Wick Photo 4

Sulfonylethyl Phosphorodiamidates

US Patent:
8093231, Jan 10, 2012
Filed:
Jul 17, 2007
Appl. No.:
11/779234
Inventors:
David R. Allen - Oak Brook IL, US
Wenli Ma - Mountain View CA, US
Brian T. Peterson - San Jose CA, US
Louise Robinson - San Carlos CA, US
Steven R. Schow - Redwood City CA, US
Songyuan Shi - Fremont CA, US
Reyna J. Simon - Los Gatos CA, US
Kevin T. Weber - Fremont CA, US
Michael M. Wick - Woodside CA, US
Assignee:
Telik, Inc. - Palo Alto CA
International Classification:
A61K 31/66, A61K 35/00, C07F 9/02
US Classification:
514102, 514114, 558157
Abstract:
Sulfonylethyl and thioethyl phosphorodiamidates, their preparation and intermediates in their preparation, formulations containing them, and their pharmaceutical use. The compounds are useful for treating cancer, alone and in combination with other anticancer therapies.


Michael Wick Photo 5

Sulfonylethyl Phosphorodiamidates

US Patent:
2005026, Dec 1, 2005
Filed:
May 20, 2005
Appl. No.:
11/134218
Inventors:
David Allen - Oak Brook IL, US
Wenli Ma - Mountain View CA, US
Brian Peterson - Mountain View CA, US
Louise Robinson - San Carlos CA, US
Steven Schow - Redwood City CA, US
Songyuan Shi - Fremont CA, US
Reyna Simon - Los Gatos CA, US
Kevin Weber - Fremont CA, US
Michael Wick - Woodside CA, US
International Classification:
A61K031/66, C07F009/02
US Classification:
514102000, 514114000, 558157000
Abstract:
Sulfonylethyl and thioethyl phosphorodiamidates, their preparation and intermediates in their preparation, formulations containing them, and their pharmaceutical use. The compounds are useful for treating cancer, alone and in combination with other anticancer therapies.